Fat Science

GLP-1 Mailbag: Weight Regain, Leptin Resistance, Hypoglycemia & Why Calories Aren’t the Problem

Fat Science

Show Notes

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor tackle a wide-ranging mailbag episode with listener questions from the U.S., UK, and Europe. Topics include unexpected weight regain on GLP-1s, post-meal sleepiness and hypoglycemia, metabolic dysfunction despite normal labs, GLP-1 dosing strategies, and why these medications are about metabolism, not appetite suppression. Key Questions Answered Why can weight regain happen on GLP-1s even when habits haven’t changed? How do leptin, ghrelin, injury, stress, and under-fueling affect weight regulation? What does it mean if you get extremely sleepy after meals—is it hypoglycemia? Do GLP-1s increase insulin in a harmful way for non-diabetics? Can you have metabolic dysfunction with normal A1C, cholesterol, and blood pressure? Do GLP-1 medications “wear off,” and how should dosing be adjusted long term? Are GLP-1s just appetite suppressants—or true metabolic treatment? Is it possible to undo decades of calorie counting and restriction-based thinking? What are the risks of the return to extreme thinness in celebrity culture? Key Takeaways Calories don’t explain metabolism. GLP-1 and GIP work across the brain and body—repairing signaling, not just reducing appetite. Leptin matters after dieting. Years of restriction and weight cycling can weaken leptin signaling, making the brain defend weight gain. Fueling is foundational. Medication can’t replace adequate food, sleep, and recovery. Post-meal fatigue is a clue. Reactive hypoglycemia is common and often misunderstood. Lowest effective dose wins. GLP-1 success is about pacing, not racing to the max dose. Chasing the “last 10 pounds” can backfire. Cosmetic restriction can create new metabolic problems. Dr. Cooper’s Actionable Tips If weight gain appears after injury or stress, focus first on sleep, regular meals, and full fueling, not restriction. Suspected hypoglycemia? Ask about a mixed meal tolerance test to assess glucose and insulin response. Stay on the lowest GLP-1 dose that’s working and adjust only when progress truly stalls. Push back on “appetite suppressant” language—these meds amplify hormones your body already makes. Notable Quote “GLP-1s aren’t about eating less—they’re about strengthening metabolic signaling” — Dr. Emily Cooper Links & Resources Podcast Home: Fat Science Podcast Website – https://fatsciencepodcast.com/ Podcast Episode References: https://fatsciencepodcast.com/wp-content/uploads/2025/06/Scientific-References-Fat-Science-Episodes.pdfCooper Center for Metabolism & Fat Science Episodes: https://coopermetabolic.com/podcast/ Resources from Dr. Cooper: https://coopermetabolic.com/resources/ Submit a Show Question: [email protected] Dr. Cooper direct show email: [email protected] Fat Science breaks diet myths and advances the science of real metabolic health. No diets, no agendas—just science that makes you feel better. This show is informational only and does not constitute medical advice.

More from Fat Science

Oct 12, 2026

Wondering why weight stalls on treatment? Dr. Emily Cooper explains how the brain defends set points and why eating less stops progress. Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener letters from around the world. The conversation addresses why athletic men with a BMI of 27 can still show high visceral fat on a DEXA scan, how medications defend metabolic set points, and why intentional undereating triggers starvation responses. The team also examines global access to metabolic treatments, dual incretin agonists versus single agonists, artificial sweeteners, and how to interpret two-hour insulin and glucose tolerance curves. Key Takeaways Rapid weight reduction without adequate nutrition can cause lean mass loss and trigger metabolic defense mechanisms. Dual incretin therapies stimulate GIP receptors far more than GLP-1 receptors compared to natural human hormones, creating different patient responses. Intentional calorie restriction reduces natural incretin production and can impair metabolic signaling, making mechanical fueling essential. Fasting insulin suppression combined with pre-diabetes indicators can reflect the brain pulling glucose during periods of low carbohydrate intake. Resources Mentioned Diabesity Foundations Course Cooper Center for Metabolism Diabesity Institute Connect with Us Podcast Home:fatsciencepodcast.com Cooper Center for Metabolism:coopermetabolic.com Diabesity Institute: diabesityinstitute.org Resources from Dr. Cooper:coopermetabolic.com/resources Join Our Community:patreon.com/cw/FatSciencePodcast Submit Your Question: [email protected] or [email protected] Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care. This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations. Produced by: Podcast Impact Studio https://podcastimpactstudio.com

Oct 5, 2026

What do new drug reports really mean for your treatment? Explore groundbreaking updates on potential diabetes and weight-loss drugs from Novo Nordisk and Eli Lilly. Dr. Emily Cooper dives into top-line results, explaining what these findings mean for those struggling with metabolic issues. KEY TAKEAWAYS Understanding the difference between efficacy estimand and treatment policy estimand.

Sep 28, 2026

Have you ever felt that diets don't work for you?

Sep 21, 2026

Can metabolic dysfunction be the cause of anxiety?

Sep 14, 2026

What's the back-to-school metabolism shift all about?

See all episodes →